KR20230145547A - 방광암의 항-pd-l1 항체 치료 - Google Patents

방광암의 항-pd-l1 항체 치료 Download PDF

Info

Publication number
KR20230145547A
KR20230145547A KR1020237034594A KR20237034594A KR20230145547A KR 20230145547 A KR20230145547 A KR 20230145547A KR 1020237034594 A KR1020237034594 A KR 1020237034594A KR 20237034594 A KR20237034594 A KR 20237034594A KR 20230145547 A KR20230145547 A KR 20230145547A
Authority
KR
South Korea
Prior art keywords
subject
bladder cancer
antigen
binding fragment
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020237034594A
Other languages
English (en)
Korean (ko)
Inventor
죤 쿨랜드
로버트 이안논
리 시
모하메드 다르
영 벤
죤 앤드류 블레이크-하스킨즈
마그달레나 자작
마를론 레벨라토
아쇼크 굽타
토니 호
질 워커
크시아오핑 진
샤논 모리스
Original Assignee
메디뮨 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메디뮨 엘엘씨 filed Critical 메디뮨 엘엘씨
Priority to KR1020257004753A priority Critical patent/KR20250025517A/ko
Publication of KR20230145547A publication Critical patent/KR20230145547A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020237034594A 2017-02-16 2018-02-16 방광암의 항-pd-l1 항체 치료 Ceased KR20230145547A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257004753A KR20250025517A (ko) 2017-02-16 2018-02-16 방광암의 항-pd-l1 항체 치료

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762459700P 2017-02-16 2017-02-16
US62/459,700 2017-02-16
PCT/US2018/018513 WO2018152415A1 (en) 2017-02-16 2018-02-16 Anti-pd-l1 antibody treatment of bladder cancer
KR1020197026803A KR20190117014A (ko) 2017-02-16 2018-02-16 방광암의 항-pd-l1 항체 치료

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197026803A Division KR20190117014A (ko) 2017-02-16 2018-02-16 방광암의 항-pd-l1 항체 치료

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257004753A Division KR20250025517A (ko) 2017-02-16 2018-02-16 방광암의 항-pd-l1 항체 치료

Publications (1)

Publication Number Publication Date
KR20230145547A true KR20230145547A (ko) 2023-10-17

Family

ID=63169615

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020237034594A Ceased KR20230145547A (ko) 2017-02-16 2018-02-16 방광암의 항-pd-l1 항체 치료
KR1020257004753A Pending KR20250025517A (ko) 2017-02-16 2018-02-16 방광암의 항-pd-l1 항체 치료
KR1020197026803A Ceased KR20190117014A (ko) 2017-02-16 2018-02-16 방광암의 항-pd-l1 항체 치료

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020257004753A Pending KR20250025517A (ko) 2017-02-16 2018-02-16 방광암의 항-pd-l1 항체 치료
KR1020197026803A Ceased KR20190117014A (ko) 2017-02-16 2018-02-16 방광암의 항-pd-l1 항체 치료

Country Status (12)

Country Link
US (2) US20190359715A1 (https=)
EP (1) EP3582805A4 (https=)
JP (2) JP2020507596A (https=)
KR (3) KR20230145547A (https=)
CN (2) CN110290803A (https=)
AU (2) AU2018221822A1 (https=)
CA (1) CA3052652A1 (https=)
EA (1) EA201991870A1 (https=)
IL (3) IL302777A (https=)
MA (1) MA47509A (https=)
SG (1) SG11201907211TA (https=)
WO (1) WO2018152415A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3142751T3 (pl) * 2014-05-13 2019-12-31 Medimmune Limited Przeciwciała anty-b7-h1 i anty-ctla-4 do leczenia niedrobnokomórkowego nowotworu płuca
KR20230145547A (ko) * 2017-02-16 2023-10-17 메디뮨 엘엘씨 방광암의 항-pd-l1 항체 치료
CN110914302A (zh) 2017-06-01 2020-03-24 赛托姆克斯治疗学股份有限公司 可活化抗pdl1抗体及其使用方法
EP4153783A1 (en) * 2020-05-21 2023-03-29 Astrazeneca AB Tumor mutational burden associated with sensitivity to immunotherapy in locally advanced or metastatic urothelial carcinoma
US20250388678A1 (en) * 2024-06-25 2025-12-25 Astrazeneca Ab Methods, Combinations, and Uses for the Treatment of Muscle Invasive Bladder Cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7947261B2 (en) * 2003-05-23 2011-05-24 Nektar Therapeutics Conjugates formed from polymer derivatives having particular atom arrangements
PL3142751T3 (pl) * 2014-05-13 2019-12-31 Medimmune Limited Przeciwciała anty-b7-h1 i anty-ctla-4 do leczenia niedrobnokomórkowego nowotworu płuca
RU2714233C2 (ru) * 2015-02-26 2020-02-13 Мерк Патент Гмбх Ингибиторы pd-1 / pd-l1 для лечения рака
ES2789500T5 (es) * 2015-05-29 2023-09-20 Hoffmann La Roche Procedimientos terapéuticos y de diagnóstico para el cáncer
US20180364240A1 (en) * 2015-12-10 2018-12-20 Medimmune, Llc Methods for treatment and selection of patients responsive to immune mediated cancer therapy
WO2017189433A1 (en) * 2016-04-25 2017-11-02 Medimmune, Llc Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies
KR20230145547A (ko) * 2017-02-16 2023-10-17 메디뮨 엘엘씨 방광암의 항-pd-l1 항체 치료

Also Published As

Publication number Publication date
WO2018152415A1 (en) 2018-08-23
US20220332828A1 (en) 2022-10-20
JP2020507596A (ja) 2020-03-12
US20190359715A1 (en) 2019-11-28
JP2024038034A (ja) 2024-03-19
EP3582805A1 (en) 2019-12-25
CA3052652A1 (en) 2018-08-23
CN118001389A (zh) 2024-05-10
EP3582805A4 (en) 2021-03-10
IL268460A (en) 2019-09-26
KR20250025517A (ko) 2025-02-21
CN110290803A (zh) 2019-09-27
EA201991870A1 (ru) 2020-02-12
MA47509A (fr) 2019-12-25
SG11201907211TA (en) 2019-09-27
AU2025201227A1 (en) 2025-03-13
AU2018221822A1 (en) 2019-09-26
IL320916A (en) 2025-07-01
KR20190117014A (ko) 2019-10-15
IL302777A (en) 2023-07-01

Similar Documents

Publication Publication Date Title
US20220332828A1 (en) Anti-pd-l1 antibody treatment of bladder cancer
WO2014194293A1 (en) Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof
TW201620547A (zh) Ｐｄ－ｌ１陰性腫瘤之組合療法
US12565528B2 (en) LAG-3 antagonist therapy for lung cancer
US20250340645A1 (en) Methods of treating tumor
JP7739269B2 (ja) がん療法のための複合バイオマーカー
US20230265188A1 (en) Lag-3 antagonist therapy for hepatocellular carcinoma
KR20240153583A (ko) 결장직장암종에 대한 병용 요법
US20240376206A1 (en) Compositions and methods for treating late stage lung cancer
CN114127315A (zh) 鉴定适合于免疫肿瘤学(i-o)疗法的受试者的方法
CN114174537A (zh) 细胞定位特征和组合疗法
WO2024196952A1 (en) Tumor subtype assessment for cancer therapy
CN116209468A (zh) 使用抗cd73和抗pd-l1抗体和化疗的治疗方法
EA045953B1 (ru) Лечение рака мочевого пузыря с помощью антитела к pd-l1
KR20250116698A (ko) Dll3-발현 암의 치료 방법

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20231010

Application number text: 1020197026803

Filing date: 20190911

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240102

Patent event code: PE09021S01D

PE0601 Decision on rejection of patent

Patent event date: 20240701

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

AMND Amendment
PX0901 Re-examination

Patent event code: PX09012R01I

Patent event date: 20241015

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20241112

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20241112

X601 Decision of rejection after re-examination
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20250213

Application number text: 1020197026803

Filing date: 20190911